Roche scales NVIDIA AI factories globally to accelerate drug discovery, diagnostics and manufacturing
Roche
Roche is deploying more than 3,500 NVIDIA Blackwell GPUs across hybrid cloud and on-premises environments in the U.S. and Europe, expanding an existing collaboration to turn AI and accelerated computing into a core operating capability across its pharmaceutical and diagnostics businesses. AI is central to Genentech's Lab-in-the-Loop drug discovery strategy, where nearly 90% of eligible small-molecule programs integrate AI; in one program a degrader molecule for oncology was designed 25% faster, and in another AI helped deliver a backup drug candidate in seven months instead of more than two years. Roche is also using NVIDIA Omniverse to build digital twins of manufacturing sites, including its new GLP-1 facility in North Carolina, uses NVIDIA Parabricks software to enable insights across vast datasets, is evaluating the BioNeMo platform for molecular design and chemistry innovation, and uses NVIDIA NeMo Guardrails to ensure safe and reliable healthcare-grade AI.
Overview
Roche is deploying more than 3,500 NVIDIA Blackwell GPUs across hybrid cloud and on-premises environments in the U.S. and Europe, expanding an existing collaboration to turn AI and accelerated computing into a core operating capability across its pharmaceutical and diagnostics businesses. AI is central to Genentech's Lab-in-the-Loop drug discovery strategy, where nearly 90% of eligible small-molecule programs integrate AI; in one program a degrader molecule for oncology was designed 25% faster, and in another AI helped deliver a backup drug candidate in seven months instead of more than two years. Roche is also using NVIDIA Omniverse to build digital twins of manufacturing sites, including its new GLP-1 facility in North Carolina, uses NVIDIA Parabricks software to enable insights across vast datasets, is evaluating the BioNeMo platform for molecular design and chemistry innovation, and uses NVIDIA NeMo Guardrails to ensure safe and reliable healthcare-grade AI.
This entry has 13 published fields tied to exact passages in an immutable source capture.
Inspect the highlighted sourceThe challenge
“When we talk about collapsing time, we’re really talking about the patients and their families who are waiting,” said Mamilli. “As an innovation-led company, using AI for this work is deeply meaningful and purpose-driven; it is exactly what we are here to do.”
The solution
Roche is deploying more than 3,500 NVIDIA Blackwell GPUs across hybrid cloud and on-premises environments in the U.S. and Europe, expanding on an existing collaboration to turn AI and accelerated computing into a core operating capability across its pharmaceutical and diagnostics businesses. With NVIDIA Blackwell and the NVIDIA BioNeMo platform running on its AI factories, Roche can train and fine-tune biological and molecular foundation models, integrate proprietary datasets and expand AI-driven lab automation, all powering Genentech's Lab-in-the-Loop drug discovery strategy. Roche is also modernizing pharmaceutical manufacturing with NVIDIA Omniverse libraries, building digital twins of production facilities to simulate and optimize complex systems before they go live, including its new GLP-1 manufacturing facility in North Carolina. Accelerated computing and NVIDIA Parabricks software enable insights across vast datasets, and in digital health Roche uses NVIDIA NeMo Guardrails to ensure safe and reliable healthcare-grade AI.
Reported business value
Nearly 90% of Genentech's eligible small-molecule programs integrate AI. In one program, a degrader molecule for oncology was designed 25% faster, and in another program, AI helped deliver a backup molecule — a secondary drug candidate developed in parallel to mitigate costly risks of failure of the first one — in seven months instead of more than two years.
Sources
Open any source and check the claim yourself — that is the point of the register.
Other pharmaceuticals entries in the register.
Novo Nordisk Scales to 2,500+ Use Cases with Secure Generative AI Using Amazon Bedrock
Novo Nordisk built a self-service generative AI platform on AWS, using Amazon Bedrock's foundation models, so employees could build and customize chatbots for nonregulated business use cases without needing to develop applications or maintain infrastructure themselves. The company worked with AWS Partner Cloud2 Oy (previously KeyCore) to validate the architecture for security and scalability. More than 25,000 Novo Nordisk employees have used the platform to create chatbots for over 2,500 unique use cases, such as retrieving information, drafting documents, or acting as a virtual colleague or critic. The company's general-purpose chatbot is used by more than 1,000 employees and processes over 26,000 prompts a month; its largest use case was trained on 140,000 documents. Each use case costs around $10 per month to run on AWS, using serverless services including Amazon DynamoDB and AWS Lambda. Building a chatbot now takes days rather than months, and some tasks that took a full day can be completed in as little as 10 minutes.
Novo Nordisk accelerates clinical insight with custom agents on Azure
Novo Nordisk wanted to accelerate pharmaceutical R&D decision-making by helping researchers explore and validate clinical hypotheses faster using AI-assisted quantitative analysis. Working with Microsoft's AI Acceleration Studio (Forward Deployed Engineering team), Novo Nordisk built a governed reasoning agent on Azure, drawing on its FounData initiative which harmonized more than 200,000 patient-years of clinical trial data aligned to CDISC, SDTM, and ADaM industry standards. The agent lets researchers ask complex scientific questions in natural language and generate and execute code against proprietary clinical datasets, with human-in-the-loop validation by biostatisticians before outputs influence decisions. Before production rollout, the teams ran thousands of automated tests and layered evaluation systems. The solution is reducing time to insight from weeks to minutes and increasing the number of scientific questions teams can evaluate from roughly 5-10 strong ideas per quarter to 50+.
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
Roche deployed 2,176 NVIDIA Blackwell GPUs on premises across the United States and Europe, bringing its combined on-premise and cloud GPU infrastructure to more than 3,500 Blackwell GPUs. The AI factory is embedded across the value chain: NVIDIA BioNeMo powers Roche's Lab-in-the-Loop strategy connecting biological and chemistry experiments with AI models in R&D; NVIDIA Omniverse-powered digital twins optimize manufacturing production lines and factory designs; accelerated computing and NVIDIA Parabricks analyze diagnostics datasets and digital pathology images; and NVIDIA NeMo Guardrails support healthcare-grade conversational AI in digital health. The expansion builds on a NVIDIA collaboration that started in 2023, and Roche's U.S. subsidiary Genentech also leverages the infrastructure for drug discovery.
Using Amazon Bedrock Agents to Accelerate Decisions Across Drug Development at AstraZeneca
AstraZeneca built Development Assistant, a multi-agent AI tool using Amazon Bedrock Agents, that lets clinical, regulatory, safety and quality teams ask natural language questions and get insights from structured and unstructured data in seconds via text-to-SQL generation and retrieval-augmented generation. A supervisor agent routes queries to specialized subagents (terminology, clinical, regulatory, database). Built on AstraZeneca's Drug Development Data Platform (3DP), the tool moved from concept to production in 6 months, including cybersecurity and AI governance checks, and is scaling to over 1,000 users.
Was this helpful?
Your feedback helps us improve our use case database